Abstract
Background: The WHO Programme for International Drug Monitoring aims to develop a comprehensive global pharmacovigilance strategy that responds to the healthcare needs of low- and middle-income countries. However, first there is a need to measure and understand existing conditions and pharmacovigilance initiatives intended in these settings. Very few investigations have carried out such a systematic assessment of the pharmacovigilance landscape in recent years in low- and middle-income countries.
Objective: To assess current and planned pharmacovigilance activities in low-and middle-income countries, identify gaps and the most urgent pharmacovigilance priorities at national and international levels, and define the elements of a sustainable global pharmacovigilance strategy.
Methods: A standardized questionnaire was sent to 114 representatives of countries participating in the WHO Programme for International Drug Monitoring (but excluding Australia, Canada, New Zealand, Switzerland and the International Conference on Harmonization countries, i.e. countries in Europe, Japan and the US) and to a few other identified contacts from non-member countries. The questionnaire was sent out between March and July 2008 and was designed to collect information on the structure, resources, functions and achievements of pharmacovigilance systems in low- and middle-income countries, with a focus on pharmacovigilance activities supported by national health authorities including public health programmes. All questionnaires that were returned by the end of July 2008 were used in the analysis.
Results: Fifty-five completed questionnaires were received by July 2008, representing a response rate of 55.5%. Forty-five percent of the pharmacovigilance centres in the analysis were established during the 1990s and 49% were set up later; 69% were affiliated with their Drug Regulatory Agency, 20% with the Ministry of Health and 9% with a university or other scientific body. Few countries (23 of 55) have any budget allocated for pharmacovigilance. Public health programmes (44%), the Global Fund to fight AIDS, Tuberculosis and Malaria (36%), universities (26%), poison centres (21%), Management Sciences for Health (18%) and Rational Use of Drugs networks (15%) sponsor some pharmacovigilance activities. In addition to direct pharmacovigilance activities, many centres are also involved in other activities such as drug information (63%), promoting patient safety (52%), rational use of drugs (46%) and poison information (15%). Some countries have sentinel sites to monitor HIV/AIDS patients (in seven countries) and other special groups. Information gathered through pharmacovigilance activities is used to assist regulatory functions in most countries (n = 42), lack of training and funding were mentioned as being major challenges to pharmacovigilance in many countries.
Conclusions: This study has helped identify some of the special challenges and barriers to promoting pharmacovigilance in low- and middle-income countries. A pharmacovigilance strategy in these settings needs to help build health systems that can serve the purpose of multiple health conditions. It needs to identify and implement feasible systems, governance, infrastructures, human resource, training and capacity building, sustainable methodologies and innovations in pharmacovigilance; a key component will be the dissemination of medicines safety information to policy makers and regulators and knowledge sharing with healthcare professionals through high quality informatics and learning tools, with rational use of medicines and patient safety as the ultimate goal of pharmacovigilance.
Similar content being viewed by others
Notes
1For the purpose of this survey, sentinel sites are defined as clinics or hospitals where a pilot programme takes place, usually to serve a particular population or to manage a particular illness/disease.
2In this survey, active surveillance is defined as the periodic follow-up of patients undergoing drug treatment where the number of persons exposed to a medication is known and recorded.
3Pharmacovigilance — the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.[5]
References
Olsson S, editor. National pharmacovigilance systems. 2nd ed. Uppsala: The Uppsala Monitoring Centre, 1999
Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation: a multi-country study. Geneva: WHO, 2002
Hughes ML, Whittlesea CMC, Luscombe DK. Review of national spontaneous reporting schemes: strengths and weaknesses. Adv Drug React Toxicol Rev 2002; 21: 231–41
Sachdev Y. Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J Pharmacol 2008; 40 Suppl. 1: S4–9
World Health Organization. The importance of pharmacovigilance. Geneva: WHO, 2002: 42
Lo Re 3rd VL, Strom BL. The role of academia and the research community in assisting the food and drug administration to ensure US drug safety. Pharmacoepidemiol Drug Saf 2007 Jul; 16(7): 818–25
Biriell C, Edwards IR. Reasons for reporting adverse drug reactions: some thoughts based on an international review. Pharmacoepidemiol Drug Saf 1997; 6: 21–6
Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health 2008; 13(9): 1143–52
Encheva D. Spontaneous reporting and continuing medical education. Uppsala Rep 2004 Apr; 25: 10–1
Sevene E, Mariano A, Mehta U, et al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf 2008; 31(10): 867–76
World Health Organization. National policy on traditional medicine and regulation of herbal medicines: report of a WHO global survey. Geneva: WHO, 2005
World Health Organization. WHO traditional medicine strategy: 2002–2005. Geneva: WHO, 2002
Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2004; 16(1): 5–19
Australian Council for Safety and Quality in Health Care. Partnerships for health in action: promoting consumer and community involvement in healthcare improvement. Canberra (ACT): Australian Council for Safety and Quality in Health Care, 2005
van Grootheest K, Graaf L, Lolkje TW, et al. Consumer adverse drug reaction reporting: a new step in pharmacovigilance. Drug Saf 2003; 26(4): 211–7
World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: WHO, 2006
Shin YS, Lee YW, Choi YH, et al. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol Drug Saf 2009 Oct; 18(10): 910–5
World Health Organization. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: WHO, 2007
Dodoo A, Adjei S, Couper M, et al. When rumours derail a mass deworming exercise. Lancet 2007; 370: 465–6
The Uppsala Monitoring Centre. Dialogue in pharmacovigilance: more effective communication. Uppsala: Uppsala Monitoring Centre, 2002
The Uppsala Monitoring Centre. Expecting the worst: anticipating, preventing and managing medicinal product crises. Uppsala: Uppsala Monitoring Centre, 2003
Pirmohamed M, Atuah KN, Dodoo A, et al. Pharmacovigilance in developing countries. BMJ 2007; 335: 462
Acknowledgements
The authors are indebted to all the National Pharmacovigilance Centre representatives who participated in this survey. The departments of Epidemiology and Global Health at the School of Public Health, University of Washington, Seattle, WA, USA, where Andy Stergachis is affiliated, were supported in part by the Bill and Melinda Gates Foundation via the University of Washington. Andy Stergachis’ departments have received a grant via Managements Sciences for Health-United States Agency for International Development (MSH-USAID) for Strengthening Pharmaceutical Systems. No other sources of funding were used to assist in the preparation of this study. None of the other authors have any conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Olsson, S., Pal, S.N., Stergachis, A. et al. Pharmacovigilance Activities in 55 Low- and Middle-Income Countries. Drug-Safety 33, 689–703 (2010). https://doi.org/10.2165/11536390-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11536390-000000000-00000